Endothelial Cell Dysfunction in Pulmonary Arterial Hyper

原发性(特发性)肺动脉高压(PPH)是多发性肺动脉高压(PAH)的一个亚型，是一种罕见的疾病，与严重的发病率和高死亡率有关。在PPH或更广泛的PAH组中，没有常规的筛查测试或疾病活动性的有效标记物。因此，患者通常出现在疾病的晚期。PPH和其他形式的PAH的发病机制尚不清楚。目前的想法集中在？两支金曲？假设：1)遗传易感性，2)触发刺激，启动肺血管损伤，导致内皮细胞功能障碍。 内皮细胞通常被释放到循环中，是研究以内皮细胞功能障碍为特征的疾病的宝贵临床材料来源。不幸的是，目前还没有明确的方法来分离临床相关数量的循环内皮细胞(CECs)。在该项目的试验台阶段，我们计划使用流式细胞术来开发一种分离临床上相关数量的可存活CECs的方法。 我们假设CEC可以用来定义PPH和其他形式的PAH中差异调节的生物标志物的子集，这可能导致更早的诊断和更好的治疗反应测量方法。我们还希望为未来的治疗干预确定新的靶点。 在项目的临床阶段，我们将招募以下受试者：1)新诊断的PPH和其他形式的PPA患者，2)归因于非血管损伤过程的肺动脉高压(PH)患者，3)正常人(对照组)。所有受试者都将接受右心导管术。通过细胞表面标志物和寡核苷酸微阵列，从外周和从肺动脉导管中提取的CECs将被表征为疾病表型。微阵列的总RNA将通过细胞分选从CEC中提取并进行扩增。此外，还将对内皮祖细胞进行定量，并分离外周血单个核细胞(PBMC)。S将利用高密度寡核苷酸芯片对其进行深入研究，以更全面地表征其转录组。我们计划通过重新研究PPH或PPA患者在治疗干预后的相同参数来跟踪治疗反应。 我们于2006年7月开始积极参加议定书的试点阶段。我们已经招收了六个人。

Primary (idiopathic) pulmonary hypertension (PPH), a subgroup of plexogenic pulmonary arterial hypertension (PAH), is a rare disorder associated with severe morbidity and high mortality rates. There are no routine screening tests or validated markers of disease activity in PPH, or the broader group of PAH. Therefore, patients usually present at advanced stages of disease. The pathogenesis of PPH and other forms of PAH remain unclear. Current thinking focuses on a ?two-hit? hypothesis: 1) genetic susceptibility, and 2) a triggering stimulus that initiates pulmonary vascular injury, resulting in endothelial cell dysfunction. Endothelial cells are normally shed into the circulation and are a valuable source of clinical material for studying diseases characterized by endothelial cell dysfunction. Unfortunately, no clear methodology exists for isolating clinically relevant numbers of circulating endothelial cells (CECs). In the bench phase of the project we plan to use flow cytometry to develop a methodology for isolating clinically relevant numbers of viable CECs. We hypothesize that CECs can be used to define a subset of differentially regulated biomarkers in PPH and other forms of PAH that may lead to earlier diagnosis and better methods for measuring responses to therapy. We also hope to identify novel targets for future therapeutic interventions. In the clinical phase of the project, we will recruit the following subject groups: 1) patients with newly diagnosed PPH and other forms of PPA, 2) patients with pulmonary hypertension (PH) ascribed to a nonvascular injury process and 3) normal individuals (controls). All subjects will undergo right heart catheterization. CECs drawn peripherally and from the pulmonary artery catheter will be characterized for disease phenotype by cell surface markers and oligonucleotide microarrays. Total RNA for microarrays will be prepared from CECs by cell sorting and subjected to amplification. In addition endothelial progenitor cells will be quantitated and peripheral blood mononuclear cells (PBMCs) will be isolated. PBMC?s will be studied in depth using high density oligonucleotide microarrays to more fully characterize their transcriptome. We plan to follow response to therapy by restudying the same parameters in patients with PPH or PPA after therapeutic intervention. We starting actively enrolling into the pilot phase of the protocol in July 2006. We have enrolled six individuals.